Sinotau Pharmaceutical is an innovative pharmaceutical company focusing on the R&D, production and clinical application of a new generation of radiopharmaceuticals. Headquartered in Beijing, the company has set up radiopharmaceutical production bases in Jiangsu, Guangdong and Sichuan, and branches in the United States. Leveraging the world’s leading R&D resources in the field of radiopharmaceuticals and precision diagnosis and treatment, Sinotau has taken the lead in deploying a variety of targeted therapies and precision diagnostic radiopharmaceuticals in the fields of tumors, neurodegenerative diseases and cardiovascular diseases. The company’s pipeline has deployed multiple radiological diagnostic and therapeutic products, some of which have entered the stage of registered clinical research.
Investors 3
Mentions in press and media 3
| Date | Title | Description | Source |
| 24.10.2023 | Life Molecular Imaging and Sinotau Pharmaceutical Group Anno... | First Amyloid PET Tracer Received Regulatory Approval in China BERLIN and BEIJING, Oct. 24, 2023 /P... | en.prnasia... |
| 03.07.2023 | China's Sinotau nets $152m to advance radiopharma pipeline a... | Beijing Sinotau International Pharmaceutical Technology (Sinotau) has secured over 1.1 billion yuan ... | dealstreet... |
| - | SinoTau | “阿IP万IPIPIP IP提示提示提示提示提示提示提示提示提示提示提示” | fastfounde... |